DOSE SELECTION FOR TOXICITY STUDIES - A PROTOCOL FOR DETERMINING THE MAXIMUM REPEATABLE DOSE

被引:2
|
作者
SPURLING, NW
CAREY, PF
机构
[1] Development Division, Glaxo Group Research Ltd, Ware, Hertfordshire
来源
HUMAN & EXPERIMENTAL TOXICOLOGY | 1992年 / 11卷 / 06期
关键词
D O I
10.1177/096032719201100603
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
1 A three-stage protocol is described for a dose-ranging study which defines the maximum repeatable dose (MRD) and provides a preview of the toxicology of new, pharmacologically active, substances before commencing the first formal regulatory toxicity studies, usually of 2 or 4 weeks duration. 2 Additionally, a range of toxicokinetic (TK) data relevant to protocol design for formal studies is generated. 3 Stage A is a dose incrementation process in which the MRD is provisionally determined and basic TK values generated. 4 In stage B the animals are dosed daily for at least 7 d, the MRD is substantiated and a wider range of TK data obtained. 5 In stage C, each of the dose levels identified for a formal study is administered once to investigate the relationship of doses to TK data. 6 This protocol can be completed using as few as 24 rats or six dogs (or primates). 7 Selection of dose levels for the first formal studies can be greatly aided by the results of a well-designed dose-ranging study including TK data. 8 For particularly toxic substances, the findings of studies based on this protocol have frequently been sufficiently clear to warrant early termination of their development.
引用
收藏
页码:449 / 457
页数:9
相关论文
共 50 条
  • [31] SODIUM MECLOFENAMATE (MECLOMEN) DOSE DETERMINING STUDIES
    WARD, JR
    BOLZAN, JA
    BRAME, CL
    CHANG, L
    GOWANS, JDC
    RAKIC, M
    ROSENBAUM, EE
    WILLKENS, RF
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1978, 23 (04): : S60 - S65
  • [32] A pilot study of individualized maximum repeatable dose (iMRD), a new dose finding system, of weekly gemcitabine for patients with metastatic pancreas cancer
    Takahashi, Y
    Mai, M
    Sawabu, N
    Nishioka, K
    PANCREAS, 2005, 30 (03) : 206 - 210
  • [33] The maximum tolerated dose for inhalation bioassays: Toxicity vs overload
    Morrow, PE
    Haseman, JK
    Hobbs, CH
    Driscoll, KE
    Vu, V
    Oberdorster, G
    FUNDAMENTAL AND APPLIED TOXICOLOGY, 1996, 29 (02): : 155 - 167
  • [34] Maximum skin dose as a predictor of toxicity from MammoSite brachytherapy
    Kim, L.
    Chen, P. Y.
    Wallace, M.
    Limbacher, A.
    Boura, J.
    Benitez, P.
    Wilson, G.
    Ghilezan, M.
    Martinez, A.
    Vicini, F. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S195 - S196
  • [35] Use of the kinetically-derived maximum dose concept in selection of top doses for toxicity studies hampers proper hazard assessment and risk management
    Heringa, Minne B.
    Cnubben, Nicole H. P.
    Slob, Wout
    Pronk, Marja E. J.
    Muller, Andre
    Woutersen, Marjolijn
    Hakkert, Betty C.
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2020, 114
  • [36] Statistical methodology to determine kinetically derived dose in repeat dose toxicity studies
    McFadden, Lisa G.
    Bartels, Michael J.
    Rick, David L.
    Price, Paul S.
    Fontaine, Donald D.
    Saghir, Shakil A.
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2012, 63 (02) : 344 - 351
  • [37] Determination of dose dependence in repeated dose toxicity studies when mid-dose alone is insignificant
    Kobayashi, Katsumi
    Pillai, Kalathil Sadasivan
    Michael, Mathews
    Cherian, Kotturathu Mammen
    Araki, Akihiro
    Hirose, Akihiko
    JOURNAL OF TOXICOLOGICAL SCIENCES, 2012, 37 (02): : 255 - 260
  • [38] COMPARATIVE TOXICITY ON LEUKOCYTES AND PLATELETS OF 2 REGIMENS OF CCNU - RELATIONSHIP BETWEEN MAXIMUM DOSE AND OPTIMUM DOSE
    ISRAEL, L
    CHAHINIAN, P
    EUROPEAN JOURNAL OF CANCER, 1973, 9 (11-1) : 799 - 802
  • [39] Naloxone reversal of clonidine toxicity: dose, dose, dose
    Seger, Donna L.
    Loden, Justin K.
    CLINICAL TOXICOLOGY, 2018, 56 (10) : 873 - 879
  • [40] Interval estimates of the probability of toxicity at the maximum tolerated dose for small samples
    Natarajan, L
    O'Quigley, J
    STATISTICS IN MEDICINE, 2003, 22 (11) : 1829 - 1836